glp 1 semaglutide or tirzepatide & are transforming diabetes & obesity management. These GLP-1 receptor agonists offer benefits from glycemic control to weight loss and cardiovascular risk reduction, emphasizing their broad impact. Read more from semaglutide vs tirzepatide difference and

Llata E, Cuffe KM, Picchetti V, Braxton JR, Torrone EA

They have been reported to reduce symptoms of angina and peripheral vascular disease, and they may improve outcomes for people with serious heart conditions, such as coronary heart disease or heart failure [5]

doi: 10.1111/dom.14831 109 MertensILVan GaalLF

Instead, discuss extending the interval between dose increases with your prescriberthis preserves therapeutic benefit while giving your body more time to adapt

Presenting the evidence to NICE, pharmaceutical company Novo Nordisk said the cardiovascular benefit was seen early in the clinical trial, before significant weight loss occurred